Glembatumumab vedotin
Based on 2 publication(s) in Google Scholar
Glembatumumab vedotin (CDX-011) is an ADC comprising a fully human IgG2 monoclonal antibody (CR011) directed against glycoprotein NMB (GPNMB) and conjugated to the potent tubulinbinding cytotoxic agent MMAE via a protease-sensitive vc linker. Glembatumumab vedotin has potent anticancer effects.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit : ≥99.0%
- CAS. Nr.: 1182215-65-1
- Molecular Weight:150000 (average)
-
Speicherung:Shipping with dry ice
-80°C, protect from light
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
- Protokoll
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
-
HY-152963
Tisotumab vedotinAntibody-Drug Conjugate -
HY-138298A
Trastuzumab deruxtecanHER2 ADC -
HY-141601
Telisotuzumab vedotinAnti-c-MET ADC -
HY-P9985
Disitamab vedotinHER2-Directed ADC -
HY-132253
Polatuzumab vedotinMicrotubule Inhibitor -
HY-132254
Sacituzumab govitecanTrop-2 ADC -
HY-P99813
Patritumab deruxtecanHER3-Directed ADC -
HY-P3239
Belantamab mafodotinAnti-BCMA ADC -
HY-P99612
Farletuzumab ecteribulinAntibody-Drug Conjugate -
HY-P99829
Cofetuzumab pelidotinPTK7 Inhibitor -
HY-P99205
GlembatumumabIgG2 Monoclonal Antibody -
HY-P99547
Trastuzumab duocarmazineHER2-targeted ADC
Publications Citing Use of MedChemExpress (MCE) Glembatumumab vedotin
More
Biologische Aktivität
Beschreibung
In Vitro
Glembatumumab vedotin binds to GPNMB on tumors, the complex is internalized and MMAE is released via proteolytic cleavage of the vc linker in a lysosomal compartment. Tumor cell death occurs as a result of microtubule inhibition by MMAE with resultant cell cycle arrest[1].
Glembatumumab vedotin (1-125 μg/mL; 96 hours) demonstrates osteosarcoma cytotoxic activity[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Osteosarcoma cell lines
-
Concentration:1 μg/mL to 125 μg/mL
-
Incubation Time:96 hours
-
Result:Demonstrated osteosarcoma cytotoxic activity.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Athymic mice (6-week-old) injected with human SK-MEL-2 and SK-MEL-5 melanoma cells[2]
-
Dosage:1.25 mg/kg, 2.5 mg/kg, 5 mg/kg, 10 mg/kg, 20 mg/kg, 40 mg/kg, 60 mg/kg, 80 mg/kg
-
Administration:i.v.; every 4 days; for 16 days
-
Result:Showed inhibition of tumor growth.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | 2011-05 | PHASE1 |
Chemical Information
-
CAS. Nr. 1182215-65-1
-
Appearance Liquid
-
Molecular Weight 150000 (average)
-
Color Colorless to light yellow
-
SMILES
[Glembatumumab vedotin]
-
Synonyms
CDX-011; CR011-vcMMAE
-
Versand
Shipping with dry ice.
-
Speicherung
-80°C, protect from light
Publications (2)
-
Journal Impact Factor
-
Most Recent
Reinheit & Dokumentation
-
Data Sheet (269 KB)
-
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
-
Handling Instructions (2659 KB)
Verweise
[1]. Christopher H Keir, et al. The use of an antibody drug conjugate, glembatumumab vedotin (CDX-011), for the treatment of breast cancer. Expert Opin Biol Ther. 2012 Feb;12(2):259-63. [Content Brief]
[2]. Vincent A Pollack, et al. Treatment parameters modulating regression of human melanoma xenografts by an antibody-drug conjugate (CR011-vcMMAE) targeting GPNMB. Cancer Chemother Pharmacol. 2007 Aug;60(3):423-35. [Content Brief]
[3]. Michael Roth, et al. Targeting Glycoprotein NMB With Antibody-Drug Conjugate, Glembatumumab Vedotin, for the Treatment of Osteosarcoma. Pediatr Blood Cancer. 2016 Jan;63(1):32-8. [Content Brief]
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Glembatumumab vedotin Related Classifications
HY-141604 Related Classifications
Powered by Bioz